Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacogenomics of Alzheimer’s and Parkinson’s diseases
Ramón Cacabelos
Neuroscience Letters (2018) Vol. 726, pp. 133807-133807
Closed Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

The impact of genetic variability on Alzheimer’s therapies: obstacles for pharmacogenetic progress
Ramón Cacabelos, Olaia Martínez-Iglesias, Natalia Cacabelos, et al.
Expert Opinion on Drug Metabolism & Toxicology (2025), pp. 1-28
Closed Access | Times Cited: 1
Sirtuins in Alzheimer’s Disease: SIRT2-Related GenoPhenotypes and Implications for PharmacoEpiGenetics
Ramón Cacabelos, Juan C. Carril, Natalia Cacabelos, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 5, pp. 1249-1249
Open Access | Times Cited: 76
Risk Factors and Pathogenesis of HIV-Associated Neurocognitive Disorder: The Role of Host Genetics
Ian Simon Olivier, Ramón Cacabelos, Vinogran Naidoo
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 11, pp. 3594-3594
Open Access | Times Cited: 62
Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions
Ramón Cacabelos, Vinogran Naidoo, Lola Corzo, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13302-13302
Open Access | Times Cited: 46
Pharmacogenetics of Anxiety and Depression in Alzheimer’s Disease
Ramón Cacabelos, Juan C. Carril, Lola Corzo, et al.
Pharmacogenomics (2023) Vol. 24, Iss. 1, pp. 27-57
Closed Access | Times Cited: 22
Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia
Ramón Cacabelos
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 9, pp. 3059-3059
Open Access | Times Cited: 48
A Review of the Recent Advances in Alzheimer’s Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics
Rima Hajjo, Dima A. Sabbah, Osama H. Abusara, et al.
Diagnostics (2022) Vol. 12, Iss. 12, pp. 2975-2975
Open Access | Times Cited: 25
Natural Bioactive Products as Epigenetic Modulators for Treating Neurodegenerative Disorders
Olaia Martínez-Iglesias, Vinogran Naidoo, Iván Carrera, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 216-216
Open Access | Times Cited: 15
How plausible is an Alzheimer’s disease vaccine?
Ramón Cacabelos
Expert Opinion on Drug Discovery (2019) Vol. 15, Iss. 1, pp. 1-6
Open Access | Times Cited: 39
Epigenetic Biomarkers as Diagnostic Tools for Neurodegenerative Disorders
Olaia Martínez-Iglesias, Vinogran Naidoo, Natalia Cacabelos, et al.
International Journal of Molecular Sciences (2021) Vol. 23, Iss. 1, pp. 13-13
Open Access | Times Cited: 30
Microorganism-Derived Molecules as Enzyme Inhibitors to Target Alzheimer’s Diseases Pathways
Thi Hanh Nguyen, San‐Lang Wang, Van Bon Nguyen
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 580-580
Open Access | Times Cited: 9
Mitochondria-Targeted Therapeutics for Alzheimer's Disease: The Good, the Bad, the Potential
Yashi Mi, Guoyuan Qi, Roberta Dı́az Brinton, et al.
Antioxidants and Redox Signaling (2020) Vol. 34, Iss. 8, pp. 611-630
Open Access | Times Cited: 23
Pharmacogenomics of Alzheimer’s Disease: Novel Strategies for Drug Utilization and Development
Ramón Cacabelos, Vinogran Naidoo, Olaia Martínez-Iglesias, et al.
Methods in molecular biology (2022), pp. 275-387
Closed Access | Times Cited: 13
Neuronally enriched microvesicle RNAs are differentially expressed in the serums of Parkinson’s patients
Morris A. Aguilar, Shauna Ebanks, Havell Markus, et al.
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 8
Drug-Drug Interactions in Prostate Cancer Treatment
Doris Hebenstreit, Renate Pichler, Isabel Heidegger
Clinical Genitourinary Cancer (2019) Vol. 18, Iss. 2, pp. e71-e82
Closed Access | Times Cited: 21
Pharmacogenomics of drugs used to treat brain disorders
Ramón Cacabelos
Expert Review of Precision Medicine and Drug Development (2020) Vol. 5, Iss. 3, pp. 181-234
Closed Access | Times Cited: 20
Nosustrophine: An Epinutraceutical Bioproduct with Effects on DNA Methylation, Histone Acetylation and Sirtuin Expression in Alzheimer’s Disease
Olaia Martínez-Iglesias, Vinogran Naidoo, Iván Carrera, et al.
Pharmaceutics (2022) Vol. 14, Iss. 11, pp. 2447-2447
Open Access | Times Cited: 12
Accelerating Alzheimer’s disease drug discovery and development: what’s the way forward?
Bruno P. Imbimbo, Stefania Ippati, Mark Watling, et al.
Expert Opinion on Drug Discovery (2021) Vol. 16, Iss. 7, pp. 727-735
Closed Access | Times Cited: 15
Associations of ARHGAP26 Polymorphisms with Alzheimer’s Disease and Cardiovascular Disease
Kesheng Wang, Yongke Lu, Deana F. Morrow, et al.
Journal of Molecular Neuroscience (2022) Vol. 72, Iss. 5, pp. 1085-1097
Closed Access | Times Cited: 11
Nanotheranostic agents for neurodegenerative diseases
Parasuraman Padmanabhan, Mathangi Palanivel, Ajay Kumar, et al.
Emerging Topics in Life Sciences (2020) Vol. 4, Iss. 6, pp. 645-675
Closed Access | Times Cited: 15
Hydrazones as novel epigenetic modulators: Correlation between TET 1 protein inhibition activity and their iron(II) binding ability
Milan Jakubek, Zdeněk Kejík, Robert Kaplánek, et al.
Bioorganic Chemistry (2019) Vol. 88, pp. 102809-102809
Closed Access | Times Cited: 14
Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics
Ramón Cacabelos, Iván Carrera, Olaia Martínez, et al.
Medicinal Research Reviews (2021) Vol. 41, Iss. 5, pp. 2841-2886
Closed Access | Times Cited: 12
TRPV4 mRNA is elevated in the caudate nucleus with NPH but not in Alzheimer’s disease
Hunter White, Ryan Webb, Ian McKnight, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 9
Pharmacogenetics of Atremorine-Induced Neuroprotection and Dopamine Response in Parkinsonʼs Disease
Ramón Cacabelos, Iván Carrera, Ramón Alejo, et al.
Planta Medica (2019) Vol. 85, Iss. 17, pp. 1351-1362
Closed Access | Times Cited: 11
Investigation of community pharmacists’ knowledge and attitudes of pharmacogenomics testing: implication for improved pharmacogenomic testing practice
Azza Ramadan, Anan S. Jarab, Ahmad Z. Al Meslamani
Human Genomics (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top